Extract obtained from several plants for use in the prevention and/or treatment of chronic inflammatory bowel diseases
Inventors
PELTIER, Sébastien • Sirvent, Pascal • OTERO, YOLANDA
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11712056-B2
Publication Date
2023-08-01
Expiration Date
Abstract
The invention relates to a composition comprising at least one specific mixture of molecules for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel diseases in humans or animals.
Core Innovation
The invention relates to plant-derived compositions for preventing and/or treating chronic inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, in a human or an animal. The compositions are based on extracts obtained from co-extracting mixtures that include Chrysanthellum indicum, Cynara scolymus, and Vaccinium myrtillus, combined with Piper and optionally piperine.
The invention provides defined botanical mixtures and different co-extracted composition options in which Chrysanthellum indicum, Cynara scolymus, and Vaccinium myrtillus are co-extracted together with Piper and/or piperine. The described composition embodiments include specific molecule sets such as apigenin-7-O-glucuronide, dicaffeoylquinic acid, monocaffeoylquinic acid, piperine, and oleuropein and hydroxytyrosol.
The invention further addresses a microbiota modulation mechanism associated with chronic IBD by improving the Bacteroidetes/Firmicutes balance and increasing Akkermansia muciniphila and Roseburia spp. In the documented animal example, supplementation with a defined composition is associated with increased Bacteroidetes and Akkermansia muciniphila and decreased Firmicutes, as assessed by 16S rRNA metagenomic analysis.
Claims Coverage
The document provides coverage for one independent method claim that includes administering a defined co-extracted plant-based composition to treat chronic inflammatory bowel disease in a human or an animal. The claim’s inventive scope is defined by the co-extracted botanical mixture structure (Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, and Piper, with optional piperine), while dependent refinements narrow the microbiota modulation endpoints, specify additional defined molecules, select Piper species, and constrain dosage forms.
Co-extracted botanical mixture including Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus and Piper
A method for treating chronic inflammatory bowel disease in a human or an animal by administering one of the compositions, wherein the composition comprises an extract obtained from co-extracting a mixture including at least Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, and Piper.
Co-extracted botanical mixture including Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus and piperine
A method for treating chronic inflammatory bowel disease in a human or an animal by administering one of the compositions, wherein the composition comprises an extract obtained from co-extracting a mixture including at least Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, and piperine.
Separated co-extracts combining Chrysanthellum indicum/Cynara scolymus/Piper with Vaccinium myrtillus
A method for treating chronic inflammatory bowel disease in a human or an animal by administering one of the compositions, wherein the composition comprises an extract obtained from co-extracting a mixture including at least Chrysanthellum indicum, Cynara scolymus, and Piper, and an extract obtained from Vaccinium myrtillus.
Separated co-extracts combining Chrysanthellum indicum/Cynara scolymus and Vaccinium myrtillus/piperine
A method for treating chronic inflammatory bowel disease in a human or an animal by administering one of the compositions, wherein the composition comprises an extract obtained from co-extracting a mixture including at least Chrysanthellum indicum and Cynara scolymus, and an extract obtained from Vaccinium myrtillus and piperine.
Separated co-extracts combining Chrysanthellum indicum/Cynara scolymus and Vaccinium myrtillus/Piper
A method for treating chronic inflammatory bowel disease in a human or an animal by administering one of the compositions, wherein the composition comprises an extract obtained from co-extracting a mixture including at least Chrysanthellum indicum and Cynara scolymus, and an extract obtained from Vaccinium myrtillus and Piper.
Separated co-extracts combining Chrysanthellum indicum/Vaccinium myrtillus and Cynara scolymus/piperine
A method for treating chronic inflammatory bowel disease in a human or an animal by administering one of the compositions, wherein the composition comprises an extract obtained from co-extracting a mixture including at least Chrysanthellum indicum, Vaccinium myrtillus, and Piper, and an extract obtained from Cynara scolymus.
Overall, the claim coverage is centered on treating chronic inflammatory bowel disease in a human or an animal by administering a plant extract composition generated from co-extracting mixtures built from Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, and Piper with optional piperine. Dependent claims refine the microbiota-related functional outcomes (including increasing Akkermansia muciniphila and rebalancing the Bacteroidetes/Firmicutes ratio), add specified molecule sets, constrain Piper to selected species, and limit the composition to specified dosage forms.
Stated Advantages
Improving the Bacteroidetes/Firmicutes balance in intestinal microbiota.
Increasing Akkermansia muciniphila in intestinal microbiota.
Increasing Roseburia spp in intestinal microbiota.
Decreasing Firmicutes in the documented animal example.
Increasing Bacteroidetes in the documented animal example.
Documented Applications
Preventing and/or treating chronic inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, in a human or an animal.
In vivo mouse supplementation context for chronic IBD-relevant intestinal microbiota changes, including shifts in Bacteroidetes, Firmicutes, and Akkermansia muciniphila assessed by 16S rRNA metagenomic analysis.
Interested in licensing this patent?